Table 5 Open in new tab Changes in...

Biomarkers of cardiac function and echocardiographic variables
N	257	259			255	251
	Mean change (SD)	Mean difference (95% CI)		Mean (SD) change	Mean difference (95% CI)
NT-proBNP ng/L	+9	−47 (143)	−57 (−81; −33)	<0.001	+26 (212)	−20 (167)	−43 (−75 to −11)	0.009
hsTnT ng/L	0.0	0.0	0.0	0.809	0.0	0.1	0.0 (0.0 to +0.1	0.113
GDF-15 ng/L	0.0	0.9	0.0	0.939	0.1	0.1	0.0 (0.0 to +0.1)	0.095
	Mean (SD) change			Mean (SD) change
QRS (ms)	0 (10)	0 (14)	0 (−2 to +2)	0.345	+1 (10)	−2 (10)	−3 (−5 to −1)	0.003
LVEDVi (mL/m²)	−2 (5)	−1 (5)	0 (−1 to +2)	0.551	−1 (4)	−1 (4)	0 (−1 to +1)	0.984
LVEF (%)	+0.7 (4.8)	+0.3 (5.3)	−0.5 (−1.7 to +0.7)	0.404	−0.4 (4.4)	+0.8 (4.2)	+1.2 (+0.2 to +2.2)	0.022
LVMi (g/m²)	0 (12)	−1 (14)	−1 (−4 to +1)	0.296	−1 (12)	−3 (13)	−2 (−4 to 0)	0.079
LAVI (mL/m²)	0 (5)	−1 (4)	−1 (−2 to 0)	0.072	0 (5)	−2 (5)	−1 (−2 to 0)	0.010
E m/s	+0.02 (0.13)	−0.04 (0.14)	−0.06 (−0.08 to −0.03)	<0.001	+0.01 (0.14)	−0.04 (0.14)	−0.05 (−0.07 to −0.02)	<0.001
A m/s	−0.01 (0.12)	−0.02 (0.12)	0.00 (−0.03 to 0.02)	0.855	0.00 (0.013)	−0.02 (0.14)	−0.01 (−0.04 to +0.01)	0.268
E/A	+0.05 (0.22)	−0.04 (0.23)	−0.10 (−0.14 to −0.05)	<0.001	+0.03 (0.30)	−0.04 (0.28)	−0.07 (−0.12 to −0.01)	0.015
E/e’	+0.05 (2.43)	−0.22 (2.3)	−0.22 (−0.68 to +0.25)	0.363	−0.02 (2.66)	−0.34 (2.30)	−0.38 (−0.83 to 0.08)	0.103
TAPSE	−0.6 (5.2)	−0.3 (5.2)	−0.1 (−1.0 to +0.9)	0.887	0.0 (5.3)	−0.3 (5.3)	−0.5 (−1.4 to +0.5)	0.305

Biomarkers of cardiac function and echocardiographic variables

One month

End of trial

Control

Spironolactone

Control

Spironolactone

257

259

255

251

Mean change (SD)

Mean difference (95% CI)

Mean (SD) change

Mean difference (95% CI)

NT-proBNP ng/L

−47 (143)

−57 (−81; −33)

<0.001

+26 (212)

−20 (167)

−43 (−75 to −11)

0.009

hsTnT ng/L

0.0

0.809

0.0

0.1

0.0 (0.0 to +0.1

0.113

GDF-15 ng/L

0.0

0.9

0.0

0.939

0.1

0.0 (0.0 to +0.1)

0.095

Mean (SD) change

QRS (ms)

0 (10)

0 (14)

0 (−2 to +2)

0.345

+1 (10)

−2 (10)

−3 (−5 to −1)

0.003

LVEDVi (mL/m²)

−2 (5)

−1 (5)

0 (−1 to +2)

0.551

−1 (4)

0 (−1 to +1)

0.984

LVEF (%)

+0.7 (4.8)

+0.3 (5.3)

−0.5 (−1.7 to +0.7)

0.404

−0.4 (4.4)

+0.8 (4.2)

+1.2 (+0.2 to +2.2)

0.022

LVMi (g/m²)

0 (12)

−1 (14)

−1 (−4 to +1)

0.296

−1 (12)

−3 (13)

−2 (−4 to 0)

0.079

LAVI (mL/m²)

0 (5)

−1 (4)

−1 (−2 to 0)

0.072

0 (5)

−2 (5)

−1 (−2 to 0)

0.010

E m/s

+0.02 (0.13)

−0.04 (0.14)

−0.06 (−0.08 to −0.03)

<0.001

+0.01 (0.14)

−0.04 (0.14)

−0.05 (−0.07 to −0.02)

<0.001

A m/s

−0.01 (0.12)

−0.02 (0.12)

0.00 (−0.03 to 0.02)

0.855

0.00 (0.013)

−0.02 (0.14)

−0.01 (−0.04 to +0.01)

0.268

E/A

+0.05 (0.22)

−0.04 (0.23)

−0.10 (−0.14 to −0.05)

<0.001

+0.03 (0.30)

−0.04 (0.28)

−0.07 (−0.12 to −0.01)

0.015

E/e’

+0.05 (2.43)

−0.22 (2.3)

−0.22 (−0.68 to +0.25)

0.363

−0.02 (2.66)

−0.34 (2.30)

−0.38 (−0.83 to 0.08)

0.103

TAPSE

−0.6 (5.2)

−0.3 (5.2)

−0.1 (−1.0 to +0.9)

0.887

0.0 (5.3)

−0.3 (5.3)

−0.5 (−1.4 to +0.5)

0.305

Biomarkers of cardiac function and echocardiographic variables
N	257	259			255	251
	Mean change (SD)	Mean difference (95% CI)		Mean (SD) change	Mean difference (95% CI)
NT-proBNP ng/L	+9	−47 (143)	−57 (−81; −33)	<0.001	+26 (212)	−20 (167)	−43 (−75 to −11)	0.009
hsTnT ng/L	0.0	0.0	0.0	0.809	0.0	0.1	0.0 (0.0 to +0.1	0.113
GDF-15 ng/L	0.0	0.9	0.0	0.939	0.1	0.1	0.0 (0.0 to +0.1)	0.095
	Mean (SD) change			Mean (SD) change
QRS (ms)	0 (10)	0 (14)	0 (−2 to +2)	0.345	+1 (10)	−2 (10)	−3 (−5 to −1)	0.003
LVEDVi (mL/m²)	−2 (5)	−1 (5)	0 (−1 to +2)	0.551	−1 (4)	−1 (4)	0 (−1 to +1)	0.984
LVEF (%)	+0.7 (4.8)	+0.3 (5.3)	−0.5 (−1.7 to +0.7)	0.404	−0.4 (4.4)	+0.8 (4.2)	+1.2 (+0.2 to +2.2)	0.022
LVMi (g/m²)	0 (12)	−1 (14)	−1 (−4 to +1)	0.296	−1 (12)	−3 (13)	−2 (−4 to 0)	0.079
LAVI (mL/m²)	0 (5)	−1 (4)	−1 (−2 to 0)	0.072	0 (5)	−2 (5)	−1 (−2 to 0)	0.010
E m/s	+0.02 (0.13)	−0.04 (0.14)	−0.06 (−0.08 to −0.03)	<0.001	+0.01 (0.14)	−0.04 (0.14)	−0.05 (−0.07 to −0.02)	<0.001
A m/s	−0.01 (0.12)	−0.02 (0.12)	0.00 (−0.03 to 0.02)	0.855	0.00 (0.013)	−0.02 (0.14)	−0.01 (−0.04 to +0.01)	0.268
E/A	+0.05 (0.22)	−0.04 (0.23)	−0.10 (−0.14 to −0.05)	<0.001	+0.03 (0.30)	−0.04 (0.28)	−0.07 (−0.12 to −0.01)	0.015
E/e’	+0.05 (2.43)	−0.22 (2.3)	−0.22 (−0.68 to +0.25)	0.363	−0.02 (2.66)	−0.34 (2.30)	−0.38 (−0.83 to 0.08)	0.103
TAPSE	−0.6 (5.2)	−0.3 (5.2)	−0.1 (−1.0 to +0.9)	0.887	0.0 (5.3)	−0.3 (5.3)	−0.5 (−1.4 to +0.5)	0.305

Table 5

Open in new tab

Changes in cardiac biomarkers and echocardiography at 1 month and final visit for participants randomised to spironolactone or control

Biomarkers of cardiac function and echocardiographic variables
	One month				End of trial
	Control	Spironolactone		P	Control	Spironolactone		P
N	257	259			255	251
	Mean change (SD)		Mean difference (95% CI)		Mean (SD) change		Mean difference (95% CI)
NT-proBNP ng/L	+9	−47 (143)	−57 (−81; −33)	<0.001	+26 (212)	−20 (167)	−43 (−75 to −11)	0.009
hsTnT ng/L	0.0	0.0	0.0	0.809	0.0	0.1	0.0 (0.0 to +0.1	0.113
GDF-15 ng/L	0.0	0.9	0.0	0.939	0.1	0.1	0.0 (0.0 to +0.1)	0.095
	Mean (SD) change				Mean (SD) change
QRS (ms)	0 (10)	0 (14)	0 (−2 to +2)	0.345	+1 (10)	−2 (10)	−3 (−5 to −1)	0.003
LVEDVi (mL/m²)	−2 (5)	−1 (5)	0 (−1 to +2)	0.551	−1 (4)	−1 (4)	0 (−1 to +1)	0.984
LVEF (%)	+0.7 (4.8)	+0.3 (5.3)	−0.5 (−1.7 to +0.7)	0.404	−0.4 (4.4)	+0.8 (4.2)	+1.2 (+0.2 to +2.2)	0.022
LVMi (g/m²)	0 (12)	−1 (14)	−1 (−4 to +1)	0.296	−1 (12)	−3 (13)	−2 (−4 to 0)	0.079
LAVI (mL/m²)	0 (5)	−1 (4)	−1 (−2 to 0)	0.072	0 (5)	−2 (5)	−1 (−2 to 0)	0.010
E m/s	+0.02 (0.13)	−0.04 (0.14)	−0.06 (−0.08 to −0.03)	<0.001	+0.01 (0.14)	−0.04 (0.14)	−0.05 (−0.07 to −0.02)	<0.001
A m/s	−0.01 (0.12)	−0.02 (0.12)	0.00 (−0.03 to 0.02)	0.855	0.00 (0.013)	−0.02 (0.14)	−0.01 (−0.04 to +0.01)	0.268
E/A	+0.05 (0.22)	−0.04 (0.23)	−0.10 (−0.14 to −0.05)	<0.001	+0.03 (0.30)	−0.04 (0.28)	−0.07 (−0.12 to −0.01)	0.015
E/e’	+0.05 (2.43)	−0.22 (2.3)	−0.22 (−0.68 to +0.25)	0.363	−0.02 (2.66)	−0.34 (2.30)	−0.38 (−0.83 to 0.08)	0.103
TAPSE	−0.6 (5.2)	−0.3 (5.2)	−0.1 (−1.0 to +0.9)	0.887	0.0 (5.3)	−0.3 (5.3)	−0.5 (−1.4 to +0.5)	0.305

Biomarkers of cardiac function and echocardiographic variables
	One month				End of trial
	Control	Spironolactone		P	Control	Spironolactone		P
N	257	259			255	251
	Mean change (SD)		Mean difference (95% CI)		Mean (SD) change		Mean difference (95% CI)
NT-proBNP ng/L	+9	−47 (143)	−57 (−81; −33)	<0.001	+26 (212)	−20 (167)	−43 (−75 to −11)	0.009
hsTnT ng/L	0.0	0.0	0.0	0.809	0.0	0.1	0.0 (0.0 to +0.1	0.113
GDF-15 ng/L	0.0	0.9	0.0	0.939	0.1	0.1	0.0 (0.0 to +0.1)	0.095
	Mean (SD) change				Mean (SD) change
QRS (ms)	0 (10)	0 (14)	0 (−2 to +2)	0.345	+1 (10)	−2 (10)	−3 (−5 to −1)	0.003
LVEDVi (mL/m²)	−2 (5)	−1 (5)	0 (−1 to +2)	0.551	−1 (4)	−1 (4)	0 (−1 to +1)	0.984
LVEF (%)	+0.7 (4.8)	+0.3 (5.3)	−0.5 (−1.7 to +0.7)	0.404	−0.4 (4.4)	+0.8 (4.2)	+1.2 (+0.2 to +2.2)	0.022
LVMi (g/m²)	0 (12)	−1 (14)	−1 (−4 to +1)	0.296	−1 (12)	−3 (13)	−2 (−4 to 0)	0.079
LAVI (mL/m²)	0 (5)	−1 (4)	−1 (−2 to 0)	0.072	0 (5)	−2 (5)	−1 (−2 to 0)	0.010
E m/s	+0.02 (0.13)	−0.04 (0.14)	−0.06 (−0.08 to −0.03)	<0.001	+0.01 (0.14)	−0.04 (0.14)	−0.05 (−0.07 to −0.02)	<0.001
A m/s	−0.01 (0.12)	−0.02 (0.12)	0.00 (−0.03 to 0.02)	0.855	0.00 (0.013)	−0.02 (0.14)	−0.01 (−0.04 to +0.01)	0.268
E/A	+0.05 (0.22)	−0.04 (0.23)	−0.10 (−0.14 to −0.05)	<0.001	+0.03 (0.30)	−0.04 (0.28)	−0.07 (−0.12 to −0.01)	0.015
E/e’	+0.05 (2.43)	−0.22 (2.3)	−0.22 (−0.68 to +0.25)	0.363	−0.02 (2.66)	−0.34 (2.30)	−0.38 (−0.83 to 0.08)	0.103
TAPSE	−0.6 (5.2)	−0.3 (5.2)	−0.1 (−1.0 to +0.9)	0.887	0.0 (5.3)	−0.3 (5.3)	−0.5 (−1.4 to +0.5)	0.305

A, late (atrial) mitral flow velocity; E, early mitral flow velocity; eʹ, early diastolic tissue velocity; GDF-15, growth differentiation factor-15; hsTnT, high-sensitivity troponin-T; LAVI, left atrial volume index; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion.

Values shown in bold are significant at a P-value <0.05

This Feature Is Available To Subscribers Only